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Abstract
Background:  ADAM33 protein is a member of the family of transmembrane glycoproteins
composed of multidomains. ADAM family members have different activities, such as proteolysis and
adhesion, making them good candidates to mediate the extracellular matrix remodelling and
changes in cellular adhesion that characterise certain pathologies and cancer development. It was
reported that one family member, ADAM23, is down-regulated by promoter hypermethylation.
This seems to correlate with tumour progression and metastasis in breast cancer. In this study, we
explored the involvement of ADAM33, another ADAM family member, in breast cancer.
Methods: First, we analysed ADAM33 expression in breast tumour cell lines by RT-PCR and
western blotting. We also used 5-aza-2'-deoxycytidine (5azadCR) treatment and DNA bisulphite
sequencing to study the promoter methylation of ADAM33 in breast tumour cell lines. We
evaluated ADAM33 methylation in primary tumour samples by methylation specific PCR (MSP).
Finally, ADAM33 promoter hypermethylation was correlated with clinicopathological data using the
chi-square test and Fisher's exact test.
Results: The expression analysis of ADAM33 in breast tumour cell lines by RT-PCR revealed gene
silencing in 65% of tumour cell lines. The corresponding lack of ADAM33 protein was confirmed
by western blotting. We also used 5-aza-2'-deoxycytidine (5-aza-dCR) demethylation and bisulphite
sequencing methodologies to confirm that gene silencing is due to ADAM33  promoter
hypermethylation. Using MSP, we detected ADAM33 promoter hypermethylation in 40% of primary
breast tumour samples. The correlation between methylation pattern and patient's
clinicopathological data was not significantly associated with histological grade; tumour stage
(TNM); tumour size; ER, PR or ERBB2 status; lymph node status; metastasis or recurrence.
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Methylation frequency in invasive lobular carcinoma (ILC) was 76.2% compared with 25.5% in
invasive ductal carcinoma (IDC), and this difference was statistically significant (p = 0.0002).
Conclusion: ADAM33 gene silencing may be related to the discohesive histological appearance of
ILCs. We suggest that ADAM33 promoter methylation may be a useful molecular marker for
differentiating ILC and IDC.
Background
ADAM33 protein is a member of the family of transmem-
brane glycoproteins composed of multidomains [1].
ADAM33 was originally identified as an asthma-suscepti-
bility gene. Several single-nucleotide polymorphisms
have been associated with asthma and bronchial hyperre-
sponsiveness [2]. ADAM33 protein contains an active site
sequence with a zinc-binding motif. It contains a glutamic
acid in the catalytic domain, and therefore it is an active
metalloproteinase [1,3]. Despite the fact that the physio-
logical function of ADAM33 remains unknown, it is capa-
ble of cleaving stem cell factor (SCF) in vitro [3]. SCF and
its receptor KIT which is known to be an oncoprotein are
involved in several cancer types [3]. The disintegrin
domain in ADAM33 can mediate integrin α9β1-depend-
ent cell adhesion [4] and can inhibit α5β1 integrin-medi-
ated cell migration [5]. The ADAM33  gene has been
mapped to human chromosome 20p13, and it consists of
22 exons [1]. The gene has CpG islands within its pro-
moter region. It was recently reported that ADAM33 is
silenced by methylation in airway epithelial cells. It shows
hypomethylation in mesenchymal cells, suggesting that
methylation controls expression in a cell type-specific
manner [6].
Recently, aberrant epigenetic gene silencing in cancer has
been reported by different groups. These findings show
the implication of these mechanisms in cancer develop-
ment [7]. ADAM23, one of the ADAM family members,
has been studied previously [8]. That study implicated
promoter hypermethylation in transcriptional silencing
in breast tumours at a more advanced stage [8]. In breast
cancer, a variety of critical genes have been shown to be
silenced by methylation (e.g., BRCA1, 14-3-3, TIM3, ESR1,
PGR and E-cadherin) [9].
In the present study, we investigated whether the
ADAM33 gene in breast tumours is regulated by epige-
netic mechanisms such as DNA methylation.
Methods
Patient samples
Frozen samples of breast tissue (n = 72) used for methyl-
ation analysis were obtained from patients treated by pri-
mary surgery for breast cancer at the Nossa Senhora das
Graças Hospital, Curitiba, Parana, Brazil, with institu-
tional approval. All patients gave informed consent for
the study to retain and analyse their tissue for research
purposes. The study included only female patients with
primary invasive breast cancer. The age of patients ranged
from 27 years to 84 years (mean 59.1 ± 13.1 years). In
most cases, the histologic type was either infiltrative duc-
tal carcinoma (IDC, n = 51 [70.8%]) or infiltrative lobular
carcinoma (ILC, n = 21 [29.2%]). Histologic grade was
determined according to the modified Bloom-Richardson
criteria as Grade 1 in 27.2% of tumours, Grade 2 in 47.1%
of tumours, and Grade 3 in 25.7% of tumours. TNM stag-
ing was done according to the official classification [10].
Immunohistochemical stains were evaluated and scored
by two pathologists who were responsible for the clinico-
pathological data. The cut-off value for estrogen receptor
(ER) and progesterone receptor (PR) status was 5% of
cells. The ERBB2 data were obtained with a HercepTestTM
(DAKO A/S, Grostrup, Denmark). When a result of +2
positive was obtained, an in situ fluorescent hybridization
(FISH) assay was performed to confirm the result. Other
clinicopathological data (tumour size, lymph node status,
local recurrence and metastasis) are summarised in
Table 1.
Cell lines
Total RNA was kindly provided by Dr Michael O'Hare
from the Ludwig Institute for Cancer Research (University
College, England) from the following breast tumour cell
lines: MDA-MB-134, MDA-MB-415, MDA-MB-175, MDA-
MB436, MDA-MB-435, MDA-MB-468, MDA-MB456, BT-
20, ZR-75-30, ZR-75-1, CAMA-1, GI101, 734B, CAL51,
MCF7, SK-B-7; SK-BR-5, SK-BR-3, PMC42 and DU4475.
The following breast cell lines, all obtained from the Lud-
wig Institute for Cancer Research (São Paulo, Brazil) were
cultured in this study: HB4a (normal epithelial immortal-
ised) [11], MDA-MB-231, MDA-MB-436, MDA-MB-435,
MCF7 and PMC42. The cell lines were cultured in RPMI
1640 medium (GIBCO/Invitrogen Life Technologies,
USA) containing 10% foetal bovine serum (comple-
mented with 0.2 mM glutamine, 40 μg/mL garamycin and
10 μg/mL insulin) at 37°C in a humidified incubator with
5% CO2.
DNA/RNA isolation of breast cell lines and breast cancer 
cells
Frozen tissue samples were dissolved in lysis buffer for
subsequent DNA isolation using the phenol/chloroform
protocol. They were then subjected to sodium bisulphiteBMC Cancer 2009, 9:80 http://www.biomedcentral.com/1471-2407/9/80
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treatment using the EpiTect® Bisulfite Kit (Qiagen). For
total RNA isolation, the TRIzol Reagent (Life Technolo-
gies, USA) was used according to the protocol supplied by
the manufacturer.
ADAM33 expression pattern
ADAM33 mRNA expression analysis was performed by
applying RT-PCR to an RNA panel of 20 breast tumour
cell lines and normal breast. HB4a was included as a nor-
mal cell line control. Reverse transcription reactions were
performed using 500 ng of DNA-free RNA, an
oligo(dT)12–18  primer and Superscript II Reverse Tran-
scriptase (Gibco, BRL). PCR was performed using
ADAM33-specific primers. The sense primer was 5' CAT
GAC ACC TTC ATG CTG, and the anti-sense primer was 5'
ATC TTG GCA TCT GGA CTT G. The PCR was performed
in a volume of 20 μl containing 1× PCR buffer (Invitro-
gen), 1.5 mM MgCl2 (Invitrogen), 200 μM dNTPs (Gibco,
BRL), 0.30 μM of each primer and 1 U of Taq Platinum
(Invitrogen). The PCR conditions were as follows: 95°C
for 12 min, 94°C for 45 s, 60°C for 45 s, 72°C for 1 min
and a final extension of 72°C for 5 min. Primers for
GAPDH were as follows: sense, 5' CTG CAC CAC CAA
CTG CTT A; anti-sense, 5' CAT GAC GGC AGG TCA GGT
C. PCR conditions were as follows: 95°C for 12 min,
94°C for 45 s, 63°C for 45 s, 72°C for 1 min and a final
extension of 72°C for 5 min. PCR products were resolved
on 1% agarose gels and visualised by ethidium bromide
staining. Hybridisations were carried out as previously
described [12] using ADAM33 or GAPDH cDNA probes
fragments corresponding to nucleotides 2191–2515 and
486–778, respectively. They were amplified using
ADAM33 RT-PCR and GAPDH RT-PCR primers, purified
from agarose gels and labelled with 32P.
Table 1: Clinicopathological parameters compared to ADAM33 promoter methylation analyzed by Chi-square Test or Fisher's Exact 
Test.
Variate na (%) ADAM33 Methylation (%) p-value
Positive Negative
Tumor Stage
0/I 14 (20.0) 4 (28.6) 10 (71.4) 0.641
II 33 (47.1) 14 (42.4) 19 (57.6)
III/IV 23 (32.9) 8 (34.8) 15 (65.2)
Tumor Sizeb
pT1/pTis 20 (27.4) 6 (30.0) 14 (70.0) 0.174
pT2 38 (52.1) 14 (36.8) 24 (63.2)
pT3/pT4 15 (20.5) 9 (60.0) 6 (40.0)
Histological Grade (SBR)
I 19 (27.1) 8 (42.1) 11 (57.9) 0.799
II 33 (47.1) 14 (42.4) 19 (57.6)
III 18 (25.7) 6 (33.3) 12 (66.7)
Lymph Node Status
Negative 34 (47.9) 13 (38.2) 21 (61.8) 0.965
Positive 37 (52.1) 15 (40.5) 22 (59.5)
Estrogen Receptor Status (ER)
Negative 12 (17.1) 4 (33.3) 8 (66.7) 0.751
Positive 58 (82.9) 24 (41.4) 34 (58.6)
ERBB2 Status
Negative 43 (66.2) 18 (41.9) 25 (58.1) 0.378
Positive 22 (33.8) 6 (27.3) 16 (72.7)
Progesterone Receptor Status (PR)
Negative 15 (24.6) 4 (26.7) 11 (73.3) 0.678
Positive 46 (75.4) 17 (36.9) 29 (63.1)
Metastasis Status
Negative 55 (79.7) 23 (41.8) 32 (58.2) 0.548
Positive 14 (20.3) 4 (28.6) 10 (71.4)
Recurrence Status
Negative 63 (91.3) 23 (36.5) 40 (63.5) 0.201
Positive 6 (8.7) 4 (66.7) 2 (33.3)
Histological Tumor Type
Invasive Ductal Carcinoma 51 (70.8) 13 (25.5) 38 (74.5) 0.0002
Invasive Lobular Carcinoma 21 (29.2) 16 (76.2) 5 (23.8)
aOnly female patients with primary invasive breast cancer were included. bAccording to TNM classification [10].BMC Cancer 2009, 9:80 http://www.biomedcentral.com/1471-2407/9/80
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Western Blotting
Western blotting to detect ADAM33 protein was per-
formed on the HB4a normal breast cell line (positive for
ADAM33 mRNA expression) as well as on the MDA-MB-
231 and MDA-MB-435 (both negative for ADAM33
mRNA expression) tumour cell lines. Protein lysates were
obtained from approximately 1.2 × 107 cells in lysis buffer
(50 mM Tris-HCl, pH 7.4, 0.5% Triton X-100 and 0.2%
sodium deoxycholate) containing protease inhibitors
(Complete, Roche). Protein samples (100 μg) were
resolved by one-dimensional 7.5% SDS-PAGE. Molecular
mass was estimated by comparison with Rainbow Molec-
ular Weight Markers (RPN 756, Amersham). Proteins
were transferred to PVDF membranes by electroblotting. A
commercial polyclonal antibody (Sigma) against the cat-
alytic domain of ADAM33 was used for immunodetec-
tion. Horseradish peroxidase-conjugated anti-rabbit
secondary antibody was used to detect the binding of pri-
mary antibody. HSP70 was detected on the blots as a con-
trol of protein integrity.
5-aza-2'deoxycytidine (5-aza-dCR) treatment
The cell lines MDA-MB-231, MDA-MB-435, and MDA-
MB-436 were analysed using this technique. Cells (106)
were incubated with 1 μM of 5-aza-dCR (Sigma Aldrich,
Deisenhein, Germany) or left untreated. Every day the
medium was changed and no significant cell death was
observed. After seven days of treatment, a reduction in cell
number was observed, and total RNA was extracted. The
expression of ADAM33 in breast tumour cells was ana-
lysed by RT-PCR using the housekeeping gene GAPDH as
an internal control. PCR products were visualised on a sil-
ver-stained 8% polyacrylamide gel. MM 10 bp (Invitro-
gen) were used as molecular weight markers.
ADAM33 CpG Island methylation analysis
Identification of the ADAM33  CpG island was accom-
plished using the human genome sequence correspond-
ing to the promoter region of the transcription start site
(TSS) of the ADAM33  gene. We identified the RefSeq
number based on the GenBank accession and submitted
the gene sequence to the Blat Search Genome at the UCSC
Genome bioinformatics website http://genome.ucsc.edu.
We selected 2000 bp of sequence extending from the 5'-
upstream region to 1000 bp downstream region of the
TSS. The sequence was submitted for analysis to the CpG-
PLOT program from the European Bioinformatics Insti-
tute website http://www.ebi.ac.uk/emboss/cpgplot.
Typical CpG islands were defined as ≥ 200 bp of sequence
that had a C+G content of ≥ 50% and a value of >0.6 for
the ratio (CpG observed)/(CpG expected) [13]. The
selected region of -472 to +389 was amplified from bisul-
phite-treated DNA samples using a nested-PCR amplifica-
tion protocol. The first set of primers included a sense
primer 5' AGG GAG TTA TGT TTT TTG TTT TGT TAG and
an anti-sense primer 5' ATT ACC TAA ACC TTC CTA TCC
TTA. PCR products were used as templates for the nested
PCR. The second set of primers included a sense primer 5'
GGG TTA GTT TAA GTA TAT TTG AG and an anti-sense
primer 5' ACA CCC AAT ACA AAT AAA TAA CC. The PCR
conditions were as follows: one round of 95°C for 12
min, 94°C for 3 min, 48°C for 3 min, 72°C for 2 min; five
cycles of 94°C 3 min, 50°C for 3 min, 72°C for 2 min;
and 35 cycles of 94°C for 1 min, 52°C for 1 min, and
72°C. Different annealing temperatures (55°C, 57°C and
59°C) were used for the nested reaction. Amplified prod-
ucts were purified using the Qiaquick Gel Extraction Kit
(Qiagen) and cloned into a pCR2.1 cloning vector (Invit-
rogen). Eight clones were sequenced for each cell line
using the vector's universal and/or reverse primers. DNA
sequencing reactions were performed using Big Dye Ter-
minator technology (Applied Biosystems) on an ABI 377
sequencer (Applied Biosystems) according to the manu-
facturer's instructions. The 100% of methylation was
obtained if cytosine in the CpG dinucleotides was present
in the eight sequenced clones. The methylation percent-
age for each tumour cell lines (global methylation pat-
tern) was calculated by dividing the number of
methylated CpG dinucleotides by the total number of
CpGs analysed.
ADAM33 Methylation-Specific PCR
Methylation-specific PCR (MSP) was performed as previ-
ously described [14]. MSP primers for the methylated con-
dition (M) included a sense primer 5'GTT TGA GGT TGT
ATC GGG TA and an anti-sense primer 5'ACT CGC AAC
TCC GAC TCC G. For the unmethylated condition (U), a
sense primer 5' GTT TGA GGT TGT ATT GGG TA and an
anti-sense primer 5' ACT CAC AAC TCC AAC TCC A were
used. The PCR protocol was one round of 95°C for 10
min; 35 cycles of 94°C for 45 s and either 66°C for meth-
ylated condition (M) or 64°C for unmethylated condition
(U) for 15 s, followed by 72°C for 45 s; and a final exten-
sion of 72°C for 5 min. PCR products were run on 8%
polyacrylamide gels and silver stained.
Statistical analysis of clinicopathological patient data
Statistical analyses were carried out using SPSS (version
12.0; SPSS, Chicago, IL). Differences were considered sta-
tistically significant when P-values were below 0.05.
Results
ADAM33 expression pattern
Using RT-PCR followed by Southern blotting hybridisa-
tion, we evaluated ADAM33 mRNA expression in a panel
of 20 breast tumour cell lines, normal breast tissue and a
normal breast cell line (HB4a). ADAM33 expression was
detected at high levels in normal tissue and in the normal
breast cell line, but it was not detected in 13 (65%) of the
20 breast tumour cell lines (Figure 1A). Western blot anal-BMC Cancer 2009, 9:80 http://www.biomedcentral.com/1471-2407/9/80
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ysis using a specific anti-ADAM33 antibody showed that
the protein was present in the positive control (cell line
HB4a) that expressed ADAM33  mRNA, but not in the
MDA-MB231 or MDA-MB435 cell lines, which also lacked
ADAM33 mRNA (Figure 1B). These results indicate that
ADAM33 is down-regulated at both the transcriptional
and translational levels in breast tumour cell lines. Two
bands reacting with ADAM33 antibody were detected at
the molecular weights of 98 and 64 kDa, which probably
correspond, respectively, to the mature form of ADAM33,
which has been processed and glycosylated, and to the
truncated form, which has been cleaved near the trans-
membrane region [15-17].
Mechanism of ADAM33 silencing by DNA methylation
To investigate the mechanism of ADAM33 transcriptional
silencing, we treated MDA-MB-435, MDA-MB-436 and
MDA-MB-231 breast tumour cell lines with the demethyl-
ating agent 5'-aza-2'deoxycytidine (5-azad-CR). The
expression of ADAM33 was restored upon treatment in all
cell lines, as detected by RT-PCR (Figure 1C).
ADAM33 CpG island methylation analyses by sodium 
bisulphite sequencing
Two putative islands were found in the ADAM33  pro-
moter region. One of the CpG islands is located between
-1012 and -748. This island has 264 bp, proximal to the
cut-off for a CpG island [13]. For this reason, we decided
to study the region from -421 to +324, which contains
part of the first exon. This region possesses promoter activ-
ity, as previously described by others [6], as well as more
than 40 transcription factor-binding sites predicted by the
TFSEARCH software (data not shown). Sodium bisulphite
sequencing was carried out on a region containing 77
CpG dinucleotides (-472 to +389), 71 of which were
located within one of the CpG islands (-421 to +324) of
the TSS (Figure 2A). We analysed the methylation pattern
of eight independent alleles (eight clones) from normal
HB4a, as well as the breast tumour cell lines PMC42,
MDA-MB-231, MDA-MB-435, MDA-MB-436 and MCF7.
Methylation of more than 80% of the CpG dinucleotides
in this region was detected in the breast tumour cell lines
analysed except PMC42 (Figure 3). All cell lines that
exhibited hypermethylation showed down-regulation of
ADAM33 expression (Figure 1A). We observed that there
are some dinucleotides that are likely to be more impor-
tant than others in transcriptional regulation. Comparing
Figure 1A with Figure 3, it is clear that ADAM33 transcripts
from cell lines with a lower methylation density were
expressed at higher levels than in cells with a higher meth-
ylation density. However, MCF7 has its ADAM33  pro-
moter region highly methylated (methylation percentage
= 86.1%), and transcription occurs to a smaller extent
(Figure 1A). These results indicate that there are crucial
CpGs that must be methylated in order to completely
silence gene transcription. These results also indicate that
the methylation density is critical to the down-regulation
of expression. In other words, hypermethylation may not
be the only factor of critical importance to transcription.
These dinucleotides may be important for the binding of
the transcription machinery, mainly because they are
located near the TSS. The methylation seems to initiate
mostly at dinucleotides 1–3 and 74–77 and to spread
towards the promoter region. These results may therefore
support the spreading model proposed by Turker [18].
Moreover, methyl-binding proteins physically associate
with methylated CpG and attract repressive complexes
such as histone deacetylases (HDAC) [19]. Different his-
tone tail modifications may exist. It is possible that the
level of gene expression for a given allele can vary from
extremely high to undetectable. Alternatively, repression
by the methyl-CpG-binding proteins can occur via mech-
anisms that do not involve histones [19]. Another possi-
bility is that the biallelic inactivation of tumour
suppressor genes involves DNA methylation, deletion or
point mutation. Furthermore, the sequence of inactivat-
ing events can occur in any order [20].
MSP analysis in primary breast tumours
The dinucleotides 47, 51, 52 and 53 lie within a region
that is differentially methylated in order to regulate
expression of ADAM33 (Figure 3). This region was chosen
ADAM33 mRNA and protein expression Figure 1
ADAM33 mRNA and protein expression. (A) The 
ADAM33 RNA panel of breast cell lines, normal breast and 
HB4a normal cells. The expected products corresponding to 
ADAM33 (328 bp) and GAPDH (290 bp) are showed. (B) 
ADAM33 western blotting. The ADAM33 bands from 
mature and cleaved forms (98 and 64 kDa) ADAM33 signal. 
HSP70 was used as control. (C) ADAM33 re-expression after 
5-azadCR treatment. MM (molecular marker 100 bp). The 
expected products were to ADAM33 (328 bp) and GAPDH 
(290 bp).
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for the design of methylation-specific PCR (MSP) primers
(Figure 2A). In the MSP reactions we tested the breast can-
cer cell lines MDA-MB-231, MCF7, PMC42, MDA-MB-
435, and MDA-MB-436 as well as the normal cell line
HB4a (Figure 2B). The MSP results corroborated the bisul-
phite sequencing and RT-PCR data for the cell lines. This
assay was subsequently used to analyse breast primary
tumour samples. Representative tumour MSP for IDC or
ILC results are shown (Figure 2C and 2D respectively).
Methylation was frequently observed in ILC (Figure 2D).
The presence of contaminating normal tissue or infiltrat-
ing lymphocytes explains the unmethylated DNA in all
tumour samples.
Descriptive chi-square and Fisher's exact tests were per-
formed in order to correlate ADAM33 promoter methyla-
tion with clinical and pathological features (Table 1).
ADAM33 promoter hypermethylation was observed in 29
of 72 (40.3%) breast cancer specimens. In a separate anal-
ysis of the histological tumour types, the difference in
methylation frequency for IDC and ILC was statistically
significant (25.5% in IDCs and 76.2% in ILCs; p =
0.0002) (Table 1, Figure 4).
Abnormal methylation of the ADAM33 promoter region
in breast carcinomas was not associated with any signifi-
cant difference in tumour stage (p = 0.641), histological
ADAM33 Methylation-Specific PCR in cell lines and in primary breast tumours Figure 2
ADAM33 Methylation-Specific PCR in cell lines and in primary breast tumours. (A) Schematic representation of the 
sequenced region of the ADAM33 gene. Positions in base pairs were calculated from the transcription start site (+1). The 
region comprises a CpG island (-421 and +324). The first exon is indicated at nucleotides +1 and +184 as a grey bar. The zoom 
shows the dinucleotide CpG in the chosen region after sequencing with designed MSP primers. The arrows represent MSP 
primers. The primers in F unmethylated (U) or methylated (M) contain the CpG dinucleotide 47 and the primers in R (U or M) 
contain the CpG dinucleotides 51, 52 and 53. (B) MSP of ADAM33 in breast carcinoma cell lines. The marker ladder 10 bp (Inv-
itrogen) was used (MM). In the negative control (NO), water was used instead of template. The presence of a visible PCR 
product (64 bp) in the lanes marked U indicates the presence of the unmethylated ADAM33 gene. The presence of a product in 
the lanes marked M indicates the presence of methylated ADAM33 gene. (C) MSP of ADAM33 in primary breast invasive ductal 
carcinomas (64 bp). MSP results from 12 representative patients are shown. (D) MSP of ADAM33 in primary breast invasive 
lobular carcinomas (64 bp). MSP results from nine representative patients are shown.
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Cytosine methylation of the ADAM33 CpG island from a normal breast cell line and in breast tumour cell lines Figure 3
Cytosine methylation of the ADAM33 CpG island from a normal breast cell line and in breast tumour cell lines. 
100% methylation means that the cytosine in that position is methylated in all eight clones sequenced. The CpGs position are 
indicate below. The arrows indicate the CpGs used for MSP primers. The global methylation and the expression status are 
indicated on the right.
Expression % Methylation
31 +++
86 -
49 ++
82 -
86 +
85 -
100
50
0
HB4a
MDA-MB-231
PMC42
MDA-MB-436
100
50
0
MCF7
100
50
0
100
50
0
100
50
0
1                  23                    35                  47  59                  71
MDA-MB-435
100
50
0
CG positionBMC Cancer 2009, 9:80 http://www.biomedcentral.com/1471-2407/9/80
Page 8 of 10
(page number not for citation purposes)
differentiation grade (SBR; p = 0.799), lymph node status
(p = 0.965), hormone receptor status (ER, p = 0.751; PR,
p = 0.678), ERBB2 status (p = 0.378) or metastasis status
(p = 0.548). The methylation frequency for all of these
variables was approximately 30–40% (Table 1). Although
no statistically significant correlation was found between
these variables and the degree of methylation, some inter-
esting features may justify future investigation. For exam-
ple, methylation frequency was higher in tumours of size
T3 and T4 than in tumours of smaller size. The methyla-
tion frequencies were similar for tumours of size T1
(30.0%) and T2 (36.8%), whereas frequencies of up to
60% were observed in tumours of size T3 and T4. How-
ever, these differences were not statistically significant (p
= 0.174). Another potentially important observation is
that in samples showing local tumour recurrence, the
ADAM33  promoter methylation frequency was 66.7%,
compared to 36.5% for non-recurrent samples (p =
0.201).
Discussion
Many studies have shown that ADAM family members
function in fundamental processes such as cell adhesion,
cell fusion, cell migration, membrane protein shedding
and proteolysis. Moreover, the shedding activity of
cytokines and growth factors seems to be related to cellu-
lar migration and to the control of several signalling path-
ways activated in cancer. For this reason, it is not
surprising that deregulated expression of ADAM family
members has been reported in human tumours [21]. In
agreement with this observation, our results show that the
ADAM33 gene is down-regulated. This probably occurs by
selective DNA hypermethylation in many breast carcino-
mas, especially those of the invasive lobular histological
type (ILC).
ILC is less common than IDC, accounting for 10–15% of
breast cancers [22]. This tumour type may appear as a pal-
pable IDC-like mass. More frequently, however, its cells
grow in single linear rows around ducts and lobules. This
so-called "Indian file" pattern of infiltration causes a
modest disruption of the underlying anatomic structures
and generates little surrounding desmoplastic stromal
reaction. This limited reaction makes diagnosis difficult
even by mammography and ultrasound [22]. The most
obvious characteristic of this histological tumour type is
the loss of E-cadherin expression, which is the major
adhesion protein in breast epithelium. Its absence
explains the histological morphology of ILC. Loss of
adhesion may also explain why ILCs tend to metastasise
to more remote locations, such as gastrointestinal and
female reproductive systems, whereas IDCs metastasise
preferentially to lung, liver and bones [23]. It is important
to note, however, that not all lobular carcinomas show a
complete loss of E-cadherin expression. In some cases,
ILCs have low levels of E-cadherin expression, implying
that alterations in the expression of other cell-to-cell adhe-
sion proteins likely occur [24]. ADAM33 may be one such
protein, since a protein of the same family (ADAM23) is
involved in cell adhesion. Moreover, it has recently been
shown that ADAM33 is capable of interacting with
integrins, suggesting its involvement in cell adhesion [4].
More studies about ADAM33 protein function in cancer
are necessary to understand its tumour-suppressor role. In
addition, we speculate that ADAM33 is involved with the
KIT oncogene pathway in cancer, given that the ADAM33
catalytic domain is capable of cleaving SCF (Kit ligand) in
vitro  [25]. We suggest the possible usefulness of both
ADAM33 promoter methylation and the lack of the pro-
tein as molecular diagnostics to differentiate IDC and ILC.
Such a differential marker may be of great value in the
clinic, since IDCs and ILCs are similar in many respects
and their histological features occasionally overlap, pri-
marily in cases of mixed carcinomas [26]. To date, E-cad-
herin is the only well-established immunohistochemical
marker for the differentiation of ductal and lobular breast
carcinomas, and few studies describe useful molecular
markers for this or other purposes [26,27]. Lobular
tumour metastases in the gastrointestinal system do not
form glands or tubular structures but instead infiltrate as
small nests and strands. These are usually of the "signet-
ring" type, making histopathological diagnosis difficult.
Moreover, ILC usually has a low mitotic rate and a uni-
form appearance. It tends to infiltrate lymph nodes in a
single-cell pattern, which makes distinguishing between
ADAM33 methylation analyses of invasive ductal carcinomas  (IDC) and invasive lobular carcinomas (ILC) Figure 4
ADAM33 methylation analyses of invasive ductal car-
cinomas (IDC) and invasive lobular carcinomas (ILC). 
The frequency of methylation was 76.2% for ILC samples and 
25.5% for IDC samples. * Indicates statistical significance (p = 
0.0002)
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lobular carcinoma cells and lymphoid cells extremely
challenging [22]. Effectively distinguishing between ILC
and IDC may be important for determining the most
appropriate treatment, since change the two types of
tumour respond differently to therapy. In fact, ILCs are
often resistant to neoadjuvant therapy.
Conclusion
In summary, our findings suggest that ADAM33 is a novel
tumour suppressor gene that may be useful as a molecular
marker for invasive lobular carcinoma of the breast. To
our knowledge, this is the first study to associate ADAM33
with breast cancer and the only data that associate
ADAM33 with a particular cancer type. Further studies are
needed to determine the immunohistochemical the
ADAM33 protein profile. Further studies are also needed
to determine the prognostic and predictive significance of
ADAM33 methylation and silencing in invasive lobular
carcinoma.
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